What is a stock summary page? Click here for an overview.
Business Description
Mainz Biomed NV
ISIN : NL0015000LC2
Description
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.91 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.54 | |||||
| Debt-to-EBITDA | -0.29 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -11.75 | |||||
| Beneish M-Score | -3.44 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -33.9 | |||||
| 3-Year EBITDA Growth Rate | 31.4 | |||||
| 3-Year EPS without NRI Growth Rate | 25.6 | |||||
| 3-Year FCF Growth Rate | 0.1 | |||||
| 3-Year Book Growth Rate | -49.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 57.13 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 38.95 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.72 | |||||
| 9-Day RSI | 36.65 | |||||
| 14-Day RSI | 37.3 | |||||
| 3-1 Month Momentum % | 20.13 | |||||
| 6-1 Month Momentum % | -47.96 | |||||
| 12-1 Month Momentum % | -87.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.32 | |||||
| Quick Ratio | 1.26 | |||||
| Cash Ratio | 1.05 | |||||
| Days Inventory | 1048.42 | |||||
| Days Sales Outstanding | 81.83 | |||||
| Days Payable | 3638.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -94.9 | |||||
| Shareholder Yield % | -188.19 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.92 | |||||
| Operating Margin % | -3133.75 | |||||
| Net Margin % | -2892.44 | |||||
| FCF Margin % | -2905.54 | |||||
| ROE % | -668 | |||||
| ROA % | -92.85 | |||||
| ROIC % | -111.68 | |||||
| 3-Year ROIIC % | -111.32 | |||||
| ROC (Joel Greenblatt) % | -418.38 | |||||
| ROCE % | -290.72 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.52 | |||||
| PB Ratio | 1.17 | |||||
| Price-to-Tangible-Book | 2.34 | |||||
| EV-to-EBIT | -0.3 | |||||
| EV-to-Forward-EBIT | -0.16 | |||||
| EV-to-EBITDA | -0.31 | |||||
| EV-to-Revenue | 8.71 | |||||
| EV-to-Forward-Revenue | 3.13 | |||||
| EV-to-FCF | -0.3 | |||||
| Price-to-GF-Value | 0.05 | |||||
| Price-to-Net-Current-Asset-Value | 10.97 | |||||
| Earnings Yield (Greenblatt) % | -333.33 | |||||
| FCF Yield % | -163.34 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MYNZ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mainz Biomed NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.397 | ||
| EPS (TTM) ($) | -25.16 | ||
| Beta | 0.89 | ||
| 3-Year Sharpe Ratio | -1.78 | ||
| 3-Year Sortino Ratio | -1.79 | ||
| Volatility % | 94.38 | ||
| 14-Day RSI | 37.3 | ||
| 14-Day ATR ($) | 0.637951 | ||
| 20-Day SMA ($) | 4.03765 | ||
| 12-1 Month Momentum % | -87.13 | ||
| 52-Week Range ($) | 2.65 - 45.2 | ||
| Shares Outstanding (Mil) | 2.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mainz Biomed NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mainz Biomed NV Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mainz Biomed NV Frequently Asked Questions
What is Mainz Biomed NV(MYNZ)'s stock price today?
The current price of MYNZ is $3.18. The 52 week high of MYNZ is $45.20 and 52 week low is $2.65.
When is next earnings date of Mainz Biomed NV(MYNZ)?
The next earnings date of Mainz Biomed NV(MYNZ) is 2025-05-15 Est..
Does Mainz Biomed NV(MYNZ) pay dividends? If so, how much?
Mainz Biomed NV(MYNZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers